https://www.washingtonpost.com/business/2023/05/09/gilead-truvada-prep-hiv-patent-case/
A federal jury in Delaware rejected claims by the U.S. government that Gilead Sciences infringed on its patents as it made billions of dollars selling Truvada for PrEP.
Create an account or login to join the discussion